Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study

作者：Okamoto Hiroshi^*; Hori Masatsugu; Matsuzaki Masunori; Tsutsui Hiroyuki; Yamazaki Tsutomu; Nagai Ryozo; Yoshikawa Tsutomu; Fujio Yasushi; Nonen Shinpei; Azuma Junichi; Izumi Tohru; Ohashi Yasuo; Kitabatake Akira

来源：International Journal of Cardiology, 2013, 164(2): 238-244.

DOI：10.1016/j.ijcard.2012.11.051

• Heart failure
• Carvedilol
• Heart rate
• Brain natriuretic peptide
• Osteopontin

Background: In chronic heart failure (CHF), it remains unclear whether the minimal dose of beta-blockade is related to survival benefits and which parameter predicts morbidity and mortality. We sought to determine the minimal dose related to survival benefits by comparing the efficacy and safety of three doses of carvedilol and the best predictive parameter for effective outcomes in Japanese patients with CHF. %26lt;br%26gt;Methods: In this prospective, randomized, stratified trial, 364 patients with mild to moderate CHF were assigned to a daily carvedilol dose of 2.5, 5, or 20 mg, plus optimal standard therapy. %26lt;br%26gt;Findings: During the mean 3-year follow-up, resting heart rate (HR) and BNP were significantly reduced with dose-response relations in the early period but without dose-response relations in the late period. The LVEF and the LVDd were increased and decreased, respectively, without a dose-response relation. No significant difference was seen in the composite primary endpoint of all-cause mortality and hospitalization for cardiovascular diseases and heart failure. Multivariate analysis indicated early decreases in HR and BNP predicted long-term outcomes. However, adverse events increased dose-dependently. Among 237 polymorphisms in 87 heart failure-related genes, the osteopontin G-156 del genotype was associated with an event-free survival rate (Wilcoxon test, P=0.030). %26lt;br%26gt;Conclusions: A low carvedilol dose is effective if the HR and/or plasma BNP has been reduced. Carvedilol therapy should be guided by reductions in HR and/or BNP, especially by initial HR reduction, but not only by its dose. OPN might be a surrogate genetic marker for long-term event-free survival.

• 出版日期2013-4-5